Pyrazolyl quinoxaline kinase inhibitors

1. A compound selected from the group consisting of a compound of formula (I)

a tautomeric form, stereochemically isomeric form and isotopic form thereof, wherein

n is an integer represents an integer equal to 0, 1, 2, 3 or 4;

R 1 is

hydrogen,

C 1-6 alkyl,

C 2-4 alkenyl,

hydroxyC 1-6 alkyl,

haloC 1-6 alkyl,

hydroxyhaloC 1-6 alkyl,

cyanoC 1-4 alkyl,

C 1-6 alkoxyC 1-6 alkyl wherein each C 1-6 alkyl is optionally substituted with one or two hydroxyl groups,

C 1-6 alkyl substituted with —NR 4 R 5 ,

C 1-6 alkyl substituted with —C(═O)—NR 4 R 5 ,

—S(═O) 2 —C 1-6 alkyl,

—S(═O) 2 -haloC 1-6 alkyl,

—S(═O) 2 —NR 14 R 15 ,

C 1-6 alkyl substituted with —S(═O) 2 —C 1-6 alkyl,

C 1-6 alkyl substituted with —S(═O) 2 -haloC 1-6 alkyl,

C 1-6 alkyl substituted with —S(═O) 2 —NR 14 R 15 ,

C 1-6 alkyl substituted with —NH—S(═O) 2 —C 1-6 alkyl,

C 1-6 alkyl substituted with —NH—S(═O) 2 -haloC 1-6 alkyl,

C 1-6 alkyl substituted with —NR 12 —S(═O) 2 —NR 14 R 15 ,

R 6 ,

C 1-6 alkyl substituted with R 6 ,

C 1-6 alkyl substituted with —C(═O)—R 6 ,

hydroxyC 1-6 alkyl substituted with R 6 ,

C 1-6 alkyl substituted with —Si(CH 3 ) 3 ,

C 1-6 alkyl substituted with —P(═O)(OH) 2 or

C 1-6 alkyl substituted with —P(═O)(OC 1-6 alkyl) 2 ;

each R 1a is independently selected from

hydrogen,

C 1-4 alkyl,

hydroxyC 1-4 alkyl,

C 1-4 alkyl substituted with amino or mono- or di(C 1-4 alkyl)amino or —NH(C 3-8 cycloalkyl),

cyanoC 1-4 alkyl,

C 1-4 alkoxyC 1-4 alkyl, and

C 1-4 alkyl substituted with one or more fluoro atoms;

each R 2 is independently selected from

hydroxyl,

halogen,

cyano,

C 1-4 alkyl,

C 2-4 alkenyl,

C 2-4 alkynyl,

C 1-4 alkoxy,

hydroxyC 1-4 alkyl,

hydroxyC 1-4 alkoxy,

haloC 1-4 alkyl,

haloC 1-4 alkoxy,

hydroxyhaloC 1-4 alkyl,

hydroxyhaloC 1-4 alkoxy,

C 1-4 alkoxyC 1-4 alkyl,

haloC 1-4 alkoxyC 1-4 alkyl,

C 1-4 alkoxyC 1-4 alkyl wherein each C 1-4 alkyl is optionally substituted with one or two hydroxyl groups,

hydroxyhaloC 1-4 alkoxyC 1-4 alkyl,

R 13 ,

C 1-4 alkyl substituted with R 13 ,

C 1-4 alkyl substituted with —C(═O)—R 13 ,

C 1-4 alkoxy substituted with R 13 ,

C 1-4 alkoxy substituted with —C(═O)—R 13 ,

—C(═O)—R 13 ,

C 1-4 alkyl substituted with —NR 7 R 8 ,

C 1-4 alkyl substituted with —C(═O)—NR 7 R 8 ,

C 1-4 alkoxy substituted with —NR 7 R 8 ,

C 1-4 alkoxy substituted with —C(═O)—NR 7 R 8 ,

—NR 7 R 8 and

—C(═O)—NR 7 R 8 ; or

when two R 2 groups are attached to adjacent carbon atoms they are optionally taken together to form a radical of formula:

—O—(C(R 17 ) 2 ) p —O—;

—X—CH═CH—; or

—X—CH═N—; wherein R 17 is hydrogen or fluorine, p is 1 or 2 and X is O or S;

R 3 is

hydroxyl,

C 1-6 alkoxy,

hydroxyC 1-6 alkoxy,

C 1-6 alkoxy substituted with —NR 10 R 11 ,

C 1-6 alkyl,

C 2-6 alkenyl,

C 2-6 alkynyl,

haloC 1-6 alkyl optionally substituted with —O—C(═O)—C 1-6 alkyl,

hydroxyC 1-6 alkyl optionally substituted with —O—C(═O)—C 1-6 alkyl,

hydroxyC 2-6 alkenyl,

hydroxyC 2-6 alkynyl,

hydroxyhaloC 1-6 alkyl,

cyanoC 1-6 alkyl,

C 1-6 alkyl substituted with carboxyl,

C 1-6 alkyl substituted with —C(═O)—C 1-6 alkyl,

C 1-6 alkyl substituted with —C(═O)—O—C 1-6 alkyl,

C 1-6 alkyl substituted with C 1-6 alkoxyC 1-6 alkyl-O—C(═O)—,

C 1-6 alkyl substituted with C 1-6 alkoxyC 1-6 alkyl-C(═O)—,

C 1-6 alkyl substituted with —O—C(═O)—C 1-6 alkyl,

C 1-6 alkoxyC 1-6 alkyl wherein each C 1-6 alkyl is optionally substituted with one or two hydroxyl groups or with —O—C(═O)—C 1-6 alkyl,

C 2-6 alkenyl substituted with C 1-6 alkoxy,

C 2-6 alkynyl substituted with C 1-6 alkoxy,

C 1-6 alkyl substituted with R 9 and optionally substituted with —O—C(═O)—C 1-6 alkyl,

C 1-6 alkyl substituted with —C(═O)—R 9 ,

C 1-6 alkyl substituted with hydroxyl and R 9 ,

C 2-6 alkenyl substituted with R 9 ,

C 2-6 alkynyl substituted with R 9 ,

C 1-6 alkyl substituted with —NR 10 R 11 ,

C 2-6 alkenyl substituted with —NR 10 R 11 ,

C 2-6 alkynyl substituted with —NR 10 R 11 ,

C 1-6 alkyl substituted with hydroxyl and —NR 10 R 11 ,

C 1-6 alkyl substituted with one or two halogens and —NR 10 R 11 ,

—C 1-6 alkyl-C(R 12 )═N—O—R 12 ,

C 1-6 alkyl substituted with —C(═O)—NR 10 R 11 ,

C 1-6 alkyl substituted with —O—C(═O)—NR 10 R 11 ,

—S(═O) 2 —C 1-6 alkyl,

—S(═O) 2 -haloC 1-6 alkyl,

—S(═O) 2 —NR 14 R 15 ,

C 1-6 alkyl substituted with —S(═O) 2 —C 1-6 alkyl,

C 1-6 alkyl substituted with —S(═O) 2 -haloC 1-6 alkyl,

C 1-6 alkyl substituted with —S(═O) 2 —NR 14 R 15 ,

C 1-6 alkyl substituted with —NR 12 —S(═O) 2 —C 1-6 alkyl,

C 1-6 alkyl substituted with —NH—S(═O) 2 -haloC 1-6 alkyl,

C 1-6 alkyl substituted with —NR 12 —S(═O) 2 —NR 14 R 15 ,

R 13 , C 1-6 alkyl substituted with —P(═O)(OH) 2 or

C 1-6 alkyl substituted with —P(═O)(OC 1-6 alkyl) 2 ;

R 4 and R 5 each independently

hydrogen,

C 1-6 alkyl,

hydroxyC 1-6 alkyl,

haloC 1-6 alkyl,

hydroxyhaloC 1-6 alkyl,

C 1-6 alkoxyC 1-6 alkyl wherein each C 1-6 alkyl is optionally substituted with one or two hydroxyl groups,

—S(═O) 2 —C 1-6 alkyl,

—S(═O) 2 -haloC 1-6 alkyl,

—S(═O) 2 —NR 14 R 15 ,

C 1-6 alkyl substituted with —S(═O) 2 —C 1-6 alkyl,

C 1-6 alkyl substituted with —S(═O) 2 -haloC 1-6 alkyl,

C 1-6 alkyl substituted with —S(═O) 2 —NR 14 R 15 ,

C 1-6 alkyl substituted with —NH—S(═O) 2 —C 1-6 alkyl,

C 1-6 alkyl substituted with —NH—S(═O) 2 -haloC 1-6 alkyl,

C 1-6 alkyl substituted with —NH—S(═O) 2 —NR 14 R 15 ,

R 13 or

C 1-6 alkyl substituted with R 13 ;

R 6 is C 3-8 cycloalkyl, C 3-8 cycloalkenyl, phenyl, 4 to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O and S; said C 3-8 cycloalkyl, C 3-8 cycloalkenyl, phenyl, 4 to 7-membered monocyclic heterocyclyl, each optionally and each independently being substituted by 1, 2, 3, 4 or 5 substituents, each substituent independently selected from cyano, C 1-6 alkyl, cyanoC 1-6 alkyl, hydroxyl, carboxyl, hydroxyC 1-6 alkyl, halogen, haloC 1-6 alkyl, hydroxyhaloC 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkoxyC 1-6 alkyl, C 1-6 alkyl-O—C(═O)—, —NR 14 R 15 , —C(═O)—NR 14 R 15 , C 1-6 alkyl substituted with —NR 14 R 15 , C 1-6 alkyl substituted with —C(═O)—NR 14 R 15 , —S(═O) 2 —C 1-6 alkyl, —S(═O) 2 -haloC 1-6 alkyl, —S(═O) 2 —NR 14 R 15 , C 1-6 alkyl substituted with —S(═O) 2 —C 1-6 alkyl, C 1-6 alkyl substituted with —S(═O) 2 -haloC 1-6 alkyl, C 1-6 alkyl substituted with —S(═O) 2 —NR 14 R 15 , C 1-6 alkyl substituted with —NH—S(═O) 2 —C 1-6 alkyl, C 1-6 alkyl substituted with —NH—S(═O) 2 -haloC 1-6 alkyl and C 1-6 alkyl substituted with —NH—S(═O) 2 —NR 14 R 15 ;

R 7 and R 8 each independently hydrogen, C 1-6 alkyl, hydroxyC 1-6 alkyl, haloC 1-6 alkyl, hydroxyhaloC 1-6 alkyl or C 1-6 alkoxyC 1-6 alkyl;

R 9 is C 3-8 cycloalkyl, C 3-8 cycloalkenyl, phenyl, naphthyl, or 3 to 12 membered monocyclic or bicyclic heterocyclyl containing at least one heteroatom selected from N, O and S, said C 3-8 cycloalkyl, C 3-8 cycloalkenyl, phenyl, naphthyl, or 3 to 12 membered monocyclic or bicyclic heterocyclyl each optionally and each independently substituted with 1, 2, 3, 4 or 5 substituents, each substituent independently selected from

═O,

C 1-4 alkyl,

hydroxyl,

carboxyl,

hydroxyC 1-4 alkyl,

cyano,

cyanoC 1-4 alkyl,

C 1-4 alkyl-O—C(═O)—,

C 1-4 alkyl substituted with C 1-4 alkyl-O—C(═O)—,

C 1-4 alkyl-C(═O)—,

C 1-4 alkoxyC 1-4 alkyl wherein each C 1-4 alkyl is optionally substituted with one or two hydroxyl groups,

halogen,

haloC 1-4 alkyl,

hydroxyhaloC 1-4 alkyl,

—NR 14 R 15 ,

—C(═O)—NR 14 R 15 ,

C 1-4 alkyl substituted with —NR 14 R 15 ,

C 1-4 alkyl substituted with —C(═O)—NR 14 R 15 ,

C 1-4 alkoxy,

—S(═O) 2 —C 1-4 alkyl,

—S(═O) 2 -haloC 1-4 alkyl,

—S(═O) 2 —NR 14 R 15 ,

C 1-4 alkyl substituted with —S(═O) 2 —NR 14 R 15 ,

C 1-4 alkyl substituted with —NH—S(═O) 2 —C 1-4 alkyl,

C 1-4 alkyl substituted with —NH—S(═O) 2 -haloC 1-4 alkyl,

C 1-4 alkyl substituted with —NH—S(═O) 2 —NR 14 R 15 ,

R 13 ,

—C(═O)—R 13 ,

C 1-4 alkyl substituted with R 13 ,

phenyl optionally substituted with R 16 ,

phenylC 1-6 alkyl wherein the phenyl is optionally substituted with R 16 , and

a 5 or 6-membered aromatic monocyclic heterocyclyl containing at least one heteroatom selected from N, O and S wherein said heterocyclyl is optionally substituted with R 16 ;

or when two of the substituents of R 9 are attached to the same atom, they are optionally taken together to form a 4 to 7-membered saturated monocyclic heterocyclyl containing at least one heteroatom selected from N, O and S;

R 10 and R 11 are each independently

hydrogen,

carboxyl,

C 1-6 alkyl,

cyanoC 1-6 alkyl,

C 1-6 alkyl substituted with —NR 14 R 15 ,

C 1-6 alkyl substituted with —C(═O)—NR 14 R 15 ,

haloC 1-6 alkyl,

hydroxyC 1-6 alkyl,

hydroxyhaloC 1-6 alkyl,

C 1-6 alkoxy,

C 1-6 alkoxyC 1-6 alkyl wherein each C 1-6 alkyl is optionally substituted with one or two hydroxyl groups,

R 6 ,

C 1-6 alkyl substituted with R 6 ,

—C(═O)—R 6 ,

—C(═O)—C 1-6 alkyl,

—C(═O)-hydroxyC 1-6 alkyl,

—C(═O)-haloC 1-6 alkyl,

—C(═O)-hydroxyhaloC 1-6 alkyl,

C 1-6 alkyl substituted with —Si(CH 3 ) 3 ,

—S(═O) 2 —C 1-6 alkyl,

—S(═O) 2 -haloC 1-6 alkyl,

—S(═O) 2 —NR 14 R 15 ,

C 1-6 alkyl substituted with —S(═O) 2 —C 1-6 alkyl,

C 1-6 alkyl substituted with —S(═O) 2 -haloC 1-6 alkyl,

C 1-6 alkyl substituted with —S(═O) 2 —NR 14 R 15 ,

C 1-6 alkyl substituted with —NH—S(═O) 2 —C 1-6 alkyl,

C 1-6 alkyl substituted with —NH—S(═O) 2 -haloC 1-6 alkyl or

C 1-6 alkyl substituted with —NH—S(═O) 2 —NR 14 R 15 ;

R 12 is hydrogen or C 1-4 alkyl optionally substituted with C 1-4 alkoxy;

R 13 is C 3-8 cycloalkyl or a saturated 4 to 6-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O and S, wherein said C 3-8 cycloalkyl or monocyclic heterocyclyl is optionally substituted with 1, 2 or 3 substituents each independently selected from halogen, hydroxyl, C 1-6 alkyl, —C(═O)—C 1-6 alkyl, C 1-6 alkoxy, and —NR 14 R 15 ;

R 14 and R 15 are each independently

hydrogen, or

haloC 1-4 alkyl,or

C 1-4 alkyl optionally substituted with a substituent selected from hydroxyl, C 1-4 alkoxy,

amino and mono- or di(C 1-4 alkyl)amino; and

R 16 is hydroxyl, halogen, cyano, C 1-4 alkyl, C 1-4 alkoxy, —NR 14 R 15 or —C(═O)NR 14 R 15 ;

or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

2. A compound according to claim 1 wherein

R 1 is

hydrogen,

C 1-6 alkyl,

hydroxyC 1-6 alkyl,

haloC 1-6 alkyl,

C 1-6 alkoxyC 1-6 alkyl wherein each C 1-6 alkyl is optionally substituted with one or two hydroxyl groups,

C 1-6 alkyl substituted with —NR 4 R 5 ,

C 1-6 alkyl substituted with —C(═O)—NR 4 R 5 ,

—S(═O) 2 —C 1-6 alkyl,

—S(═O) 2 —NR 14 R 15 ,

C 1-6 alkyl substituted with —S(═O) 2 —C 1-6 alkyl,

C 1-6 alkyl substituted with —NH—S(═O) 2 —C 1-6 alkyl,

R 6 ,

C 1-6 alkyl substituted with R 6 ,

C 1-6 alkyl substituted with —C(═O)—R 6 ,

hydroxyC 1-6 alkyl substituted with R 6 , or

C 1-6 alkyl substituted with —Si(CH 3 ) 3 ;

each R 1a is hydrogen;

R 10 and R 11 are each independently

hydrogen,

C 1-6 alkyl,

cyanoC 1-6 alkyl,

C 1-6 alkyl substituted with —NR 14 R 15 ,

C 1-6 alkyl substituted with —C(═O)—NR 14 R 15 ,

haloC 1-6 alkyl,

hydroxyC 1-6 alkyl,

hydroxyhaloC 1-6 alkyl,

C 1-6 alkoxy,

C 1-6 alkoxyC 1-6 alkyl wherein each C 1-6 alkyl is optionally substituted with one or two hydroxyl groups,

R 6 ,

C 1-6 alkyl substituted with R 6 ,

—C(═O)—R 6 ,

—C(═O)—C 1-6 alkyl,

—C(═O)-hydroxyC 1-6 alkyl,

—C(═O)-haloC 1-6 alkyl,

—C(═O)-hydroxyhaloC 1-6 alkyl,

C 1-6 alkyl substituted with —Si(CH 3 ) 3 ,

—S(═O) 2 —C 1-6 alkyl,

—S(═O) 2 -haloC 1-6 alkyl,

—S(═O) 2 —NR 14 R 15 ,

C 1-6 alkyl substituted with —S(═O) 2 —C 1-6 alkyl,

C 1-6 alkyl substituted with —S(═O) 2 -haloC 1-6 alkyl,

C 1-6 alkyl substituted with —S(═O) 2 —NR 14 R 15 ,

C 1-6 alkyl substituted with —NH—S(═O) 2 —C 1-6 alkyl,

C 1-6 alkyl substituted with —NH—S(═O) 2 -haloC 1-6 alkyl or

C 1-6 alkyl substituted with —NH—S(═O) 2 —NR 14 R 15 ;

or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

3. A compound according to claim 1 wherein each R 1a is hydrogen; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

4. A compound according to claim 1 wherein R 1 is C 1-6 alkyl; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

5. A compound according to claim 1 wherein R 1 is CH 3 — or CD 3 -; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

6. A compound according to claim 1 wherein R 2 is independently selected from halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 1-4 alkoxy, hydroxyC 1-4 alkyl, hydroxyC 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkoxyC 1-4 alkyl, R 13 , C 1-4 alkoxy substituted with R 13 , —C(═O)—R 13 , C 1-4 alkyl substituted with NR 7 R 8 , C 1-4 alkoxy substituted with NR 7 R 8 , —NR 7 R 8 and —C(═O)—NR 7 R 8 ; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

7. A compound according to claim 6 wherein R 2 is C 1-4 alkyloxy; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

8. A compound according to claim 6 wherein R 2 is CH 3 O— or CD 3 O—; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

9. A compound according to claim 1 wherein R 3 is

C 1-6 alkyl,

hydroxyC 1-6 alkyl,

hydroxyhaloC 1-6 alkyl,

haloC 1-6 alkyl,

C 1-6 alkyl substituted with —C(═O)—C 1-6 alkyl,

C 1-6 alkoxyC 1-6 alkyl wherein each C 1-6 alkyl is optionally substituted with one or two hydroxyl groups,

C 1-6 alkyl substituted with R 9 ,

C 1-6 alkyl substituted with —NR 10 R 11 ,

C 1-6 alkyl substituted with hydroxyl and —NR 10 R 11 ,

C 1-6 alkyl substituted with one or two halogens and —NR 10 R 11 ,

C 1-6 alkyl substituted with —C(═O)—O—C 1-6 alkyl,

C 1-6 alkyl substituted with —O—C(═O)—NR 10 R 11 ,

C 1-6 alkyl substituted with carboxyl,

C 1-6 alkyl substituted with —NR 12 —S(═O) 2 —C 1-6 alkyl,

C 1-6 alkyl substituted with —NR 12 —S(═O) 2 —NR 14 R 15 ,

C 1-6 alkyl substituted with hydroxyl and R 9 ,

—C 1-6 alkyl-C(R 12 )═N—O—R 12 ,

C 1-6 alkyl substituted with —C(═O)—NR 10 R 11 ,

C 1-6 alkyl substituted with —C(═O)—R 9 ,

C 2-6 alkynyl substituted with R 9 ,

hydroxyC 1-6 alkoxy,

C 2-6 alkenyl,

C 2-6 alkynyl or

R 13 ;

or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

10. A compound according to claim 1 wherein R 1 is C 1-6 alkyl, each R 1a is hydrogen, n is an integer equal to 2, each R 2 is C 1-4 alkoxy, and R 3 is C 1-6 alkyl substituted with —NR 10 R 11 ; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

11. A compound according to claim 10 wherein R 10 is hydrogen or C 1-6 alkyl, and R 11 is hydrogen, C 1-6 alkyl, haloC 1-6 alkyl, —C(═O)—C 1-6 alkyl, —S(═O) 2 —C 1-6 alkyl, —S(═O) 2 —NR 14 R 15 , hydroxyC 1-6 alkyl, —C(═O)-hydroxyhaloC 1-6 alkyl, —C(═O)—R 6 , cyanoC 1-6 alkyl, R 6 , C 1-6 alkyl substituted with R 6 , —C(═O)-haloC 1-6 alkyl, or C 1-6 alkyl substituted with —Si(CH 3 ) 3 ; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

12. A compound according to claim 10 wherein R 10 is hydrogen, —CH 3 , —CH 2 CH 3 or —CH(CH 3 ) 2 and R 11 is hydrogen, —CH 3 , —CH 2 CH 3 , —CH(CH 3 ) 2 , —CH 2 CF 3 , —CH 2 CHF 2 , —CH 2 CH 2 F, —C(═O)—CH 3 , —S(═O) 2 —CH 3 , —S(═O) 2 —CH 2 CH 3 , —S(═O) 2 —CH(CH 3 ) 2 , —S(═O) 2 —N(CH 3 ) 2 , —CH 2 CH 2 OH, —C(═O)—C(OH)(CH 3 )CF 3 , —C(═O)-cyclopropyl, —CH 2 CH 2 CN, cyclopropane, cyclopentane, 2,2,6,6-tetramethyl-piperidine, —CH 2 C 3 H 5 , —CH 2 -tetrahydrofuran, —C(═O)-(1-methyl-piperidin-3-yl), —C(═O)—CF 3 , —CH 2 Si(CH 3 ) 3 , or —CH 2 —C 6 H 5 ; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

13. A compound according to claim 10 wherein R 1 is —CH 3 , each R 1a is hydrogen, n is an integer equal to 2, each R 2 is CH 3 O—, and R 3 is —CH 2 CH 2 NHCH(CH 3 ) 2 ; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

14. A compound according to claim 10 wherein R 1 is —CH 3 , each R 1a is hydrogen, n is an integer equal to 2, each R 2 is CH 3 O—, R 3 is —CH 2 CH 2 —CH 2 —NHCH 2 CF 3 ; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

15. A compound according to claim 10 wherein R 1 is —CH 3 , each R 1a is hydrogen, n is an integer equal to 2, each R 2 is CH 3 O—, R 3 is —CH 2 CH 2 NH 2 ; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

16. A compound according to claim 1 wherein the compound is N-(3,5-dimethoxyphenyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]-N′-(2,2,2-trifluoroethyl)propane-1,3-diamine; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

17. The compound N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

18. A compound according to claim 1 wherein the compound is N-(3,5-dimethoxyphenyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

19. A combination comprising a compound according to claim 1 ; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and another anticancer agent.

20. A combination according to claim 19 , wherein the compound is selected from:

N-(3,5-dimethoxyphenyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]-N′-(2,2,2-trifluoroethyl)propane-1,3-diamine;

N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine; and

N-(3,5-dimethoxyphenyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine;

or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

21. A pharmaceutical composition comprising a compound according to claim 1 ; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and a pharmaceutically acceptable carrier.

22. A pharmaceutical composition comprising a compound according to claim 16 , or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and a pharmaceutically acceptable carrier.

23. A pharmaceutical composition comprising a compound according to claim 17 ; or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and a pharmaceutically acceptable carrier.

24. A pharmaceutical composition comprising a compound according to claim 18 , or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and a pharmaceutically acceptable carrier.

25. A combination according to claim 19 , wherein the anticancer agent is A kinase inhibitor.

26. A compound according to claim 16 wherein the compound is N-(3,5-dimethoxyphenyl)-N- [3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]-N′-(2,2,2-trifluoroethyl)propane-1,3-diamine.

27. A compound according to claim 17 wherein the compound is N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine.

28. A compound according to claim 18 wherein the compound is N-(3,5-dimethoxyphenyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine.

29. A combination according to claim 20 , wherein the compound is selected from:

N-(3,5-dimethoxyphenyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]-N′-(2,2,2-trifluoroethyl)propane-1,3-diamine;

N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4- yl)quinoxalin-6-yl]ethane-1,2-diamine; and

N-(3,5-dimethoxyphenyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine.

30. A combination according to claim 20 , where the anticancer agent is a kinase inhibitor.

31. A combination according to claim 29 , where the anticancer agent is a kinase inhibitor.

32. A pharmaceutical composition comprising a compound according to claim 26 , and a pharmaceutically acceptable carrier.

33. A pharmaceutical composition comprising a compound according to claim 27 , and a pharmaceutically accepatable carrier.

34. A pharmaceutical composition comprising a compound according to claim 28 , and a pharmaceutically accepatable carrier.

35. A combination according to claim 20 , wherein the compound is

N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine.

36. A combination according to claim 35 , where the anticancer agent is a kinase inhibitor.